Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT02057172 · ClinicalTrials.gov registry record · Phase 2
Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes
A Phase 2 study, sponsored by Hanmi Pharmaceutical Company Limited.
- Completed
- Registry status
- Phase 2
- Development phase
- 254
- Enrollment target
NCT02057172 is a Phase 2 study that has completed, run by Hanmi Pharmaceutical Company Limited. The registered enrollment target is 254 participants.
The verdict
NCT02057172, a Phase 2 study, has completed, sponsored by Hanmi Pharmaceutical Company Limited.
- COMPLETED
- Registry status
- Phase 2
- Development phase
- 254 participants
- Enrollment target
Study Summary
The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
Interventions
- DRUG Placebo
- DRUG liraglutide
- DRUG HM11260C
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 254 participants |
| Start Date | 2014-01 |
| Est. Completion | 2014-12 |
| Phase | Phase 2 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT02057172
The ClinicalTrials.gov registry entry for NCT02057172 describes a study currently listed as completed, categorized as Phase 2. The registered enrollment target is 254 participants, a figure that helps gauge the scale of data the investigators plan to collect. The listed sponsor is Hanmi Pharmaceutical Company Limited, which has 25 total studies on file at ClinicalTrials.gov.
The record links to 0 conditions, and to 3 interventions - of which Placebo is the first listed.
NCT02057172 reports 0 study locations.
Frequently Asked Questions
What is clinical trial NCT02057172 about?
NCT02057172 is a clinical study titled "Glycaemic Control of Weekly LAPS-Exendin Versus Placebo in Subjects of Type 2 Diabetes". The purpose of this study is to determine the optimal dose or doses of HM11260C, when administered once a week under the skin, to improve the control of blood sugar levels in patients with early-stage type 2 diabetes mellitus (T2DM).
What is the current status of trial NCT02057172?
This trial is currently completed. It is a Phase 2 study. The enrollment target is 254 participants. The study started on 2014-01. Estimated completion is 2014-12.
What interventions are being tested in trial NCT02057172?
The interventions under investigation include: Placebo (DRUG), liraglutide (DRUG), HM11260C (DRUG).
Who is sponsoring clinical trial NCT02057172?
This trial is sponsored by Hanmi Pharmaceutical Company Limited, which has 25 total clinical trials registered on ClinicalTrials.gov.
Learn More About Clinical Trials
Explore more on PlainTrial
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.